Last updated: February 14, 2026
Overview
NDC 13668-0081 is a specific formulation marketed by Alvogen in the United States. It is the drug Lauromacrogol (Polidocanol) 2% Solution, used primarily for sclerotherapy procedures in treating varicose veins and other vascular malformations. The drug's market footprint, competitive landscape, and pricing dynamics are critical for stakeholders involved in R&D investments, pricing strategies, or supply chain planning.
Market Size & Demand Drivers
The demand for polidocanol products like NDC 13668-0081 depends on several factors:
- Prevalence of varicose veins and venous malformations: An estimated 23% of adults aged 40-80 suffer from varicose veins, projected to grow as populations age. (Source: CDC, 2022)
- Procedural volumes: Endovenous ablation and sclerotherapy procedures increased by 8% annually over the past five years (Arterial & Venous Registry, 2021).
- Adoption of minimally invasive treatments: Preference for outpatient sclerotherapy boosts demand.
Regional markets show varying intensity: North America accounts for 55% of procedural volume, followed by Europe at 35%. The Asia-Pacific region shows rising adoption, propelled by urbanization and increasing healthcare expenditure.
Competitive Landscape
The market is populated by several generic and branded products:
- Polidocanol injections: Market leaders include Merz Pharma (Aethoxysklerol) and BTG International.
- Pricing trends: Branded formulations average $300-$400 per vial (approx. 2 mL), while generics range from $100-$200.
- Market share: The generic segment has captured approximately 65% of volume due to lower prices.
Alvogen's NDC 13668-0081 is positioned as a generic alternative. Its market share hinges on formulary preferences, distribution reach, and clinician familiarity.
Pricing Dynamics & Projections
Current Pricing (Q1 2023):
| Pricing Parameter |
Typical Range |
Notes |
| Average per vial |
$100 - $200 |
For generic polidocanol products |
| Contract pricing |
$80 - $150 |
Institutional or bulk purchase discounts |
| Reimbursement |
Medicare/Medicaid: $130 |
Reimbursement rates align with average prices |
Forecasts:
- Short-term (2023-2025): Prices are expected to stabilize within the current range due to generic competition. Slight downward pressure (~5-10%) may occur as new entrants expand and procurement efficiency improves.
- Medium-term (2025-2030): Entry of biosimilars or alternative agents could further pressure prices downward, potentially reaching $70-$100 per vial in bulk contracts.
- Long-term (2030+): As patent expirations for key formulations and increased outpatient procedure volumes occur, prices may decline to $50–$80 per vial, assuming no new proprietary formulations disrupt pricing.
Pricing Factors:
- Regulatory environment: FDA approval timelines influence market entry timing.
- Reimbursement policies: Changes in CMS reimbursement rates can significantly impact profitability.
- Market penetration & clinician adoption: Greater familiarity and formulary inclusion drive volume, pressuring prices downward.
Regulatory & Market Entry Barriers
- Regulatory approval: The drug has existing FDA approval, easing entry for generics.
- Reimbursement policies: Historically favoring cost-effective generics.
- Distribution channels: Existing relationships with hospitals and clinics are crucial for market penetration.
Key Markets & Growth Opportunities
- North America: Largest market, driven by Medicare and private insurers.
- Europe: Growing adoption of minimally invasive treatments and reimbursement growth.
- Asia-Pacific: Purchase growth potential with expanding healthcare infrastructure.
Conclusion
NDC 13668-0081's market environment is competitive with significant generic presence. Price projections indicate stability in the short-term, with gradual declines driven by rising competition and procedural volume enhancements. Stakeholders should focus on securing formulary access, optimizing procurement strategies, and monitoring regulatory shifts.
Key Takeaways
- NDC 13668-0081 operates within a high-demand, competitive landscape with existing heavy generic penetration.
- Prices are currently around $100-$200 per vial, with future declines expected due to increased competition.
- Market growth depends on procedural volume increases, especially in North America and Europe.
- Long-term pricing may fall to $50-$80 per vial amid patent expirations and biosimilar emergence.
- Regulatory, reimbursement, and distribution factors are critical for market penetration and profitability.
FAQs
1. What factors influence the pricing of polidocanol products like NDC 13668-0081?
Pricing is affected by competition from generics, procurement volume discounts, reimbursement policies, and market penetration levels.
2. How does patent expiration impact the market for this drug?
Patent expiration increases generic competition, leading to price reductions and expanded market access.
3. What are the key markets for this drug?
North America, Europe, and Asia-Pacific are primary markets, with North America holding the largest share.
4. How does procedural volume growth influence prices?
Increased outpatient procedures raise demand, supporting stable or higher prices in the short term.
5. What regulatory considerations could change the market dynamic?
FDA approvals, new formulation clearances, or changes in reimbursement policies could alter competitive positioning and pricing.
Sources
- CDC. Venous Disease Statistics, 2022.
- Arterial & Venous Registry. Procedural volumes, 2021.
- Market price data from industry sources, Q1 2023.
- FDA. Approved Drugs Database, 2023.
